ClinicalTrials.gg
RecruitingNCT07628127Updated Oct 13, 2026

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

A Phase 1 interventional study of VRB-103 and Placebo in Obesity and Overweight, sponsored by Verdiva Bio Dev Limited. Recruiting at 3 sites in Australia. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Verdiva Bio Dev Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 13, 2026Enrollment updatedEligibility revised+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 187 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
61st of 168
332 · median 184
Started
2026
with 39 others
Phase 1
32 of 187
14 open now
Primary completion
2028-03
later than 45 of 73 live
Registered
172nd of 187
by date

Among the 187 studies in Obesity with a site in Australia, this one is the 61st largest by planned enrollment of the 168 interventional ones that give a count, is one of 40 that started in 2026, is one of 32 in phase 1, reaches primary completion later than 45 of the 73 other live ones, and was the 172nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 187 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 187 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.

Read the detailed description

For Arm 1 (single ascending dose [SAD] part), the primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen to participants with elevated body mass index (BMI) (≥25 kg/m\^2 and ≤35 kg/m\^2) who are otherwise healthy. For Arm 2 and Arm 3 (multiple ascending dose [MAD] parts), the primary objective is to evaluate the safety and tolerability of multiple ascending doses of VRB-103 tablets administered as monotherapy, VRB-101 tablets administered as monotherapy, or VRB-103 tablets administered in combination with VRB-101 tablets to participants with elevated BMI (≥27 kg/m\^2 and ≤40 kg/m\^2) who are otherwise healthy.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Glucagon-like peptide-1 (GLP-1)
  • Recombinant human amylin analog
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female assigned at birth, inclusive of all gender identities.
  2. Have ≤6.4% at Screening and Day -2 eligibility confirmation.
  3. Have a of:

    1. ≥25 kg/m\^2 and ≤35.0 kg/m\^2 (Arm 1) OR
    2. ≥27 kg/m\^2 and ≤40.0 kg/m\^2 (Arm 2 and Arm 3)
  4. Weight ≥70 kg with self-reported stable body weight (≤5% body weight change) for the 3 months prior to randomization.
  5. Otherwise healthy, as defined by the absence of any , in the Investigator's opinion, active or chronic disease (e.g., Type 2 diabetes mellitus [T2DM], cardiovascular [CV] disease, cancer, and any acute or chronic illness that could pose a problem to completing the study) as determined through a comprehensive medical and surgical history, a thorough physical exam (PE) that includes vital signs, a 12-lead (ECG), hematology, blood chemistry, serology, and urinalysis. Cardiovascular (CV) risk factors, such as dyslipidemia and mild hypertension, are expected and are allowed.
  6. Have an estimated (eGFR) >60 mL/min at Screening and Day -2 eligibility confirmation, as calculated using the 2021 Chronic Kidney Disease Epidemiology (CKD-EPI) creatinine equation, with no other clinical or laboratory evidence of renal dysfunction or impairment.
  7. Persons of must be non-pregnant and non-lactating and must agree to use study-specified methods.
  8. Have a resting BP of ≤140/90 millimeters of mercury (mmHg) at Screening and Day -2 eligibility confirmation (an average of duplicate readings) with 2 or less hypertension-directed medications.

Exclusion criteria

Exclusion Criteria:

  1. Have any prior diagnosis of type 1 diabetes mellitus or T2DM, or other forms of diabetes mellitus. A participant with a history of gestational diabetes may be included in the study if the participant has ≤6.4% at Screening and Day -2 eligibility confirmation and is not on medication to lower glucose.
  2. Have at least 1 laboratory value suggestive of diabetes at Screening and Day -2 eligibility confirmation, including 1 or more of HbA1c >6.4% (48 mmol/mol) or random glucose ≥200 mg/dL (11.1 mmol/L).
  3. Have had exposure to GLP-1, glucose-dependent insulinotropic peptide (GIP), or amylin analogs within 6 months prior to Screening or any prior history of known or suspected /allergies, intolerability, or lack of efficacy to these medications. Have known or suspected hypersensitivity to study product(s), to amylin analogs, to selective GLP-1 receptor agonist (RAs), or to GIP/GLP-1 or GLP-1/glucagon dual RAs.
  4. Presence or history of cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric, malignant, metabolic, endocrinological, hematological, or venereal disorder, as judged by the Investigator.
  5. Have a medical history of clinically significant gastric emptying abnormality (for example, severe gastroparesis or gastric outlet obstruction), chronically take drugs that directly affect gastrointestinal (GI) motility, or have a history of any clinically relevant GI diseases or symptoms of GI disorders potentially affecting interpretation of study data.
  6. Have a history of hypocalcemia or ionized serum calcium below the normal range at Screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
332 participants (estimated)

Study arms

  • Experimental
    Arm 1, SAD

    Each participant will receive a single oral dose of VRB-103 alone, VRB-103 co-administered with VRB-101, or placebo once.

    Drug: VRB-103 · Other: Placebo · Drug: VRB-101

  • Experimental
    Arm 2, MAD

    Each participant will receive multiple oral doses of VRB-103 or placebo.

    Drug: VRB-103 · Other: Placebo

  • Experimental
    Arm 3, MAD

    Each participant will receive multiple oral doses of VRB-103 alone, VRB-101 alone, VRB-103 co-administered with VRB-101, or placebo.

    Drug: VRB-103 · Other: Placebo · Drug: VRB-101

Interventions

  • DrugVRB-103

    VRB-103 tablets will be administered orally.

  • OtherPlacebo

    Placebo tablets will be administered orally.

  • DrugVRB-101

    VRB-101 tablets will be administered orally.

    Also known as: Oral Ecnoglutide

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Any clinically significant changes in lab parameters, hematology, ECG parameters, will be reported as TEAEs.

    Time frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

  2. Number of Participants with Adverse Events of Special Interest (AESIs)

    Time frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

  3. Change in Columbia-Suicide Severity Rating Scale (C-SSRS) from Baseline

    The C-SSRS systematically assesses suicidal ideation and behavior using yes/no questions, ordinal severity ratings (0-5), and intensity subscales. Results at End of Study will be compared to Baseline.

    Time frame: Screening up to Day 8 (Arm 1) or End of Treatment (Arm 2: Week 7 and Arm 3: Week 17)

  4. Change in Patient Health Questionnaire-9 (PHQ-9) Scores from Baseline

    The PHQ-9 is a 9-item validated assessment, measures the severity of depression. Each item is rated from 0 to 3, for a total score out of 27. A score of 15-19 indicates moderately severe depression, and a score of 20-27 indicates severe depression.

    Time frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

Secondary outcomes

  1. Plasma concentrations of VRB-103 and VRB-101

    Time frame: Baseline up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

  2. Maximum Observed Plasma Concentration (Cmax) for VRB-103 and VRB-101

    Time frame: Baseline up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

  3. Time to Reach Cmax (Tmax) for VRB-103 and VRB-101

    Time frame: Baseline up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

  4. Area Under the Plasma Concentration-time Curve Extrapolated to Infinity (AUCinf) for VRB-103 and VRB-101

    Time frame: Arm 1: From Baseline up to Day 29

  5. Half-life (t1/2) for VRB-103 and VRB-101

    Time frame: Baseline up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)

  6. Trough Concentration (Ctrough) of VRB-103 and VRB-101

    Time frame: Baseline up to End of Study (Arm 2: Week 10 and Arm 3: Week 20)

  7. AUC Over the Dosing Interval (AUCtau) of VRB-103 and VRB-101

    Time frame: Baseline up to End of Study (Arm 2: Week 10 and Arm 3: Week 20)

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Mar 2028, 20 months after the start.

Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 20 months is above that.

Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2026
First posted
Jun 4, 2026
StartActual
Jul 6, 2026
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (2 Australia)
  • Nucleus Network · Brisbane, Australia
  • Veritus · Melbourne, Australia
Oct 13, 2026
Enrollment
336→332
Oct 13, 2026
Eligibility
3 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • Edited≥25 kg/m\^2 and ≤35.0 kg/m\^2 (Part AArm 1) OR
  • Edited≥27 kg/m\^2 and ≤40.0 kg/m\^2 (Part BArm 2 and Part CArm 3)
  • EditedHave a resting BP of ≤140/90 millimeters of mercury (mmHg) at Screening and Day -2 eligibility confirmation (an average of duplicate readings) with 2 or less hypertension-directed medications.
Exclusion criteria
  • EditedHave a history of hypocalcemia or ionized serum calcium below the normal range at Screening and Day -2 eligibility confirmation.
Oct 13, 2026
Interventions
Arm changed Arm 1, SAD: VRB-103 or VRB-101 or Placebo→Arm 1, SAD; Arm 2, MAD: VRB-103 or VRB-101 or Placebo→Arm 2, MAD; Arm 3, MAD: VRB-103 or VRB-101 or Placebo→Arm 3, MAD
Oct 13, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameChange in Columbia-Suicide Severity Rating Scale (C-SSRS) from BaselineScreening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20) → Screening up to Day 8 (Arm 1) or End of Treatment (Arm 2: Week 7 and Arm 3: Week 17)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    2 sites added
    Show 2 added (2 Australia)
    • Nucleus Network · Brisbane, Australia
    • Veritus · Melbourne, Australia
    Enrollment 336→332
    Eligibility 3 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • Edited≥25 kg/m\^2 and ≤35.0 kg/m\^2 (Part AArm 1) OR
    • Edited≥27 kg/m\^2 and ≤40.0 kg/m\^2 (Part BArm 2 and Part CArm 3)
    • EditedHave a resting BP of ≤140/90 millimeters of mercury (mmHg) at Screening and Day -2 eligibility confirmation (an average of duplicate readings) with 2 or less hypertension-directed medications.
    Exclusion criteria
    • EditedHave a history of hypocalcemia or ionized serum calcium below the normal range at Screening and Day -2 eligibility confirmation.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameChange in Columbia-Suicide Severity Rating Scale (C-SSRS) from BaselineScreening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20) → Screening up to Day 8 (Arm 1) or End of Treatment (Arm 2: Week 7 and Arm 3: Week 17)
    Interventions Arm changed Arm 1, SAD: VRB-103 or VRB-101 or Placebo→Arm 1, SAD; Arm 2, MAD: VRB-103 or VRB-101 or Placebo→Arm 2, MAD; Arm 3, MAD: VRB-103 or VRB-101 or Placebo→Arm 3, MAD

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07628127
Lead sponsor
Verdiva Bio Dev Limited
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Jul 6, 2026
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Verdiva Bio Medical Affairs
Contact
medical.affairs@verdivabio.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion